David M Cherba
Overview
Explore the profile of David M Cherba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sameni M, Tovar E, Essenburg C, Chalasani A, Linklater E, Borgman A, et al.
Clin Cancer Res
. 2015 Oct;
22(4):923-34.
PMID: 26432786
Purpose: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is associated with poor clinical outcome. There is a vital need for effective targeted therapeutics for TNBC patients,...
2.
Monsma D, Cherba D, Eugster E, Dylewski D, Davidson P, Peterson C, et al.
Am J Cancer Res
. 2015 Jun;
5(4):1507-18.
PMID: 26101714
Variable clinical responses, tumor heterogeneity, and drug resistance reduce long-term survival outcomes for metastatic melanoma patients. To guide and accelerate drug development, we characterized tumor responses for five melanoma patient...
3.
Monsma D, Cherba D, Richardson P, Vance S, Rangarajan S, Dylewski D, et al.
Pediatr Blood Cancer
. 2014 Apr;
61(9):1570-7.
PMID: 24687871
Background: Precision (Personalized) medicine has the potential to revolutionize patient health care especially for many cancers where the fundamental disease etiology remains either elusive or has no available therapy. Here...
4.
Monks N, Cherba D, Kamerling S, Simpson H, Rusk A, Carter D, et al.
J Transl Med
. 2013 Jul;
11:158.
PMID: 23815880
Background: A successful therapeutic strategy, specifically tailored to the molecular constitution of an individual and their disease, is an ambitious objective of modern medicine. In this report, we highlight a...
5.
Monsma D, Monks N, Cherba D, Dylewski D, Eugster E, Jahn H, et al.
J Transl Med
. 2012 Jun;
10:125.
PMID: 22709571
Background: There is resurgence within drug and biomarker development communities for the use of primary tumorgraft models as improved predictors of patient tumor response to novel therapeutic strategies. Despite perceived...
6.
Lee C, Dykema K, Hawkins D, Cherba D, Webb C, Furge K, et al.
PLoS One
. 2011 Mar;
6(2):e17165.
PMID: 21365009
Mitogen-activated protein kinase kinases (MKK or MEK) 1 and 2 are usually treated as redundant kinases. However, in assessing their relative contribution towards ERK-mediated biologic response investigators have relied on...